Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.47 |
| ▸ | KIT | P10721 | 2/20 | 0.47 |
| ▸ | CKS1B | P61024 | 2/20 | 0.47 |
| ▸ | SKP1 | P63208 | 2/20 | 0.47 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | SMO | Q99835 | 1/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.45 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3390869 | 0.87 | RET (0.49) | RETMAPTLMNAGPR119KIT | |
| SCHEMBL30323222 | 0.87 | KIT (0.48) | RETMAPTLMNAGPR119KIT | |
| SCHEMBL908053 | 0.87 | RET (0.49) | RETMAPTLMNAGPR119KIT | |
| SCHEMBL2366069 | 0.87 | MEN1 (0.57) | MAPTLMNAGPR119KITCKS1B | |
| SCHEMBL22712188 | 0.87 | KIT (0.48) | RETMAPTLMNAGPR119KIT | |
| SCHEMBL24125815 | 0.87 | GPR119 (0.51) | MAPTLMNAGPR119KITCKS1B | |
| SCHEMBL30851276 | 0.86 | MEN1 (0.61) | RETMAPTLMNAGPR119KIT | |
| SCHEMBL2365916 | 0.86 | MEN1 (0.61) | RETMAPTLMNAGPR119KIT | |
| SCHEMBL10317392 | 0.86 | GBA1 (0.48) | RETMAPTLMNAGPR119KIT | |
| SCHEMBL2365638 | 0.85 | RET (0.47) | RETMAPTLMNAGPR119KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2565182-B1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORP (JP) | 2017-10-11 | — | — | EP | disclosed |
| CN-102239152-B | Novel amide derivative and use thereof as medicine | MITSUBISHI TANABE PHARMA CORP. (JP) | 2014-10-29 | — | — | CN | disclosed |
| US-8816079-B2 | Amide derivative and use thereof as medicine | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-08-26 | — | — | US | disclosed |
| EP-2364975-B1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-06-12 | — | — | EP | disclosed |
| CN-102971291-A | Novel amide derivative and use thereof as medicine | MITSUBISHI TANABE PHARMA CORP | 2013-03-13 | — | — | CN | disclosed |
| EP-2565182-A1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | Mitsubishi Tanabe Pharma Corporation (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-20130040930-A1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-02-14 | — | — | US | disclosed |
| US-8354401-B2 | Oxazolidinone amide aromatic compounds for supressing MMP-9 production | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-01-15 | — | — | US | disclosed |
| CN-102239152-A | Novel amide derivative and use thereof as medicine | MITSUBISHI TANABE PHARMA CORP | 2011-11-09 | — | — | CN | disclosed |
| US-20110263571-A1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-10-27 | — | — | US | disclosed |
| EP-2364975-A1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040930-A1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | MMP9, MMP10, MMP2 | RET 4670/4885MAPT 4490/4885LMNA 4091/4885 |
| US-20110263571-A1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | MMP9, MMP10, MMP2 | RET 4697/4885MAPT 3728/4885LMNA 3668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.